Skip to main content

Vaxxinity, Inc. (VAXX)

Vaxxinity will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Capn/a
Revenue (ttm)134,000
Net Income (ttm)-87.78M
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About VAXX

Vaxxinity is a purpose-driven biotechnology company committed to democratizing healthcare across the globe. Our vision is to disrupt the existing treatment paradigm for chronic diseases. We believe our synthetic peptide vaccine platform has the potential to enable a new class of therapeutics that will improve the quality and convenience of care, reduce costs and increase access to treatments for a wide range of indications. Our Vaxxine Platform is designed to harness the immune system to convert the body into its own “drug factory,” stimula...

IndustryBiotechnology
IPO DatePending
CEOMei Mei Hu
Employees75
Stock ExchangeNASDAQ
Ticker SymbolVAXX
Full Company Profile

Financial Performance

Financial Statements

News

Vaccine biotech Vaxxinity files for a $100 million IPO

Vaxxinity, a Phase 2 biotech developing vaccine therapies for chronic diseases using synthetic peptides, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

2 weeks ago - Renaissance Capital

Vaxxinity IPO Registration Document (S-1)

Vaxxinity, Inc. has filed to go public with an IPO on the NASDAQ.

2 weeks ago - SEC